AstraZeneca’s Iressa Produces Effect In Subpopulation, ASCO Data Show
This article was originally published in Pharmaceutical Approvals Monthly
Results of an initial Phase II study aimed at identifying responders to AstraZeneca's non-small cell lung cancer agent Iressa suggest further research could support approval in a subpopulation, researchers said at the recent American Society of Clinical Oncology meeting in Orlando, Fla
You may also be interested in...
AstraZeneca Iressa European Marketing Authorization Application withdrawn following the non-small cell lung cancer therapy’s failure to show a survival benefit in recent study. FDA is expected to provide an update on the status of gefitinib’s Subpart H approval in January or February
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011